Akero Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
© -
Hey, folks. I'm Tiago Fauth, biotech analyst here at Crédit Suisse. I just want to welcome the Akero Therapeutics team for a presentation this afternoon. We have Tim. So yes, you guys can take it away.
Good afternoon, good morning, and welcome to the Akero presentation. My name is Tim Rolph. I'm the Chief Scientific Officer and 1 of the 2 Co-Founders of Akero. Today's presentation will focus on the clinical data we generated earlier this year in our BALANCED study in biopsy-proven NASH. And these are the highlights that I'm going to talk about during the course of this presentation. We saw very substantial improvements in terms of reducing liver fat, ranging from amongst the highest to the highest reported. We saw a substantial reduction in liver injury, indicated by 40% reduction in liver enzyme activity levels. And we saw encouraging signs based on ELF and Pro-C3 that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |